

Supplementary Table 1 Receiver operating characteristic analysis for overall survival in patients with distal cholangiocarcinoma after pancreatoduodenectomy

Variables	Cut-off value	AUC	Sensitivity	Specificity
CA19-9	235.8	0.661	0.383	0.907
PLR	143	0.637	0.759	0.507
NLR	3.1	0.672	0.624	0.680
LMR	3.2	0.654	0.362	0.347
NMR	11.2	0.555	0.376	0.773
APRI	0.3	0.503	0.880	0.184
ABR	0.3	0.632	0.489	0.227
ICPI	445.4	0.636	0.706	0.560
SII	682.0	0.667	0.674	0.627
SIRI	1.5	0.674	0.546	0.747

CA19-9: Carbohydrate antigen 19-9; PLR: Platelet-to-lymphocyte ratio; NLR: Neutrophil to lymphocyte ratio; LMR: Lymphocyte to monocyte ratio; NMR: Neutrophil-to-monocyte ratio; APRI: Aspartate transaminase-to-platelet; ABR: Albumin to bilirubin ratio; ICPI: Inflammation-combined prognostic index; SII: Systemic immune-inflammation index; SIRI: Systemic inflammatory response index.

Supplementary Table 2 Receiver operating characteristic analysis for recurrence-free survival in patients with distal cholangiocarcinoma after pancreatoduodenectomy

Variables	Cut-off value	AUC	Sensitivity	Specificity
CA19-9	69.3	0.661	0.620	0.621

PLR	159.8	0.569	0.661	0.484
NLR	2.8	0.556	0.686	0.453
LMR	1.1	0.533	0.975	0.053
NMR	11.5	0.516	0.339	0.758
APRI	1.7	0.503	0.165	0.895
ABR	3.7	0.604	0.050	0.958
ICPI	445.4	0.568	0.678	0.463
SII	496.6	0.565	0.760	0.358
SIRI	1.1	0.543	0.694	0.411

AUC: Area under curve; CA19-9: Carbohydrate antigen 19-9; PLR: Platelet-to-lymphocyte ratio; NLR: Neutrophil to lymphocyte ratio; LMR: Lymphocyte to monocyte ratio; NMR: Neutrophil-to-monocyte ratio; APRI: Aspartate transaminase-to-platelet; ABR: Albumin to bilirubin ratio; ICPI: Inflammation-combined prognostic index; SII: Systemic immune-inflammation index; SIRI: Systemic inflammatory response index.